Immunoconjugates
Showing 26 - 50 of 113
HER2 Positive Metastatic Breast Cancer Trial in Worldwide (ARX788)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
-
Glendale, California
- +52 more
Oct 25, 2022
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,
Recruiting
- Early-stage Breast Cancer
- +6 more
- Anastrozole
- +2 more
-
Fullerton, California
- +8 more
Sep 19, 2022
Malignant Glioma Trial in Durham (D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three
Recruiting
- Malignant Glioma
- D2C7-IT (6920 ng/mL via convection-enhanced delivery)
- +2 more
-
Durham, North CarolinaDuke University Medical Center
Mar 22, 2022
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter
Recruiting
- Locally Advanced Bladder Urothelial Carcinoma
- +18 more
- Enfortumab Vedotin
- Erdafitinib
-
Los Angeles, California
- +2 more
Jun 28, 2022
Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)
Recruiting
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Jan 25, 2023
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,
Recruiting
- High Grade Serous Ovarian Cancer
- +2 more
- Upifitimab rilsodotin
- Placebo
-
Phoenix, Arizona
- +40 more
Jan 25, 2023
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Solid Tumor Trial in United States (OBT076, a CD205-directed antibody-drug conjugate)
Recruiting
- Solid Tumor
- OBT076, a CD205-directed antibody-drug conjugate
-
Los Angeles, California
- +5 more
Jan 10, 2022
Triple-negative Breast Cancer Trial (IMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus
Withdrawn
- Triple-negative Breast Cancer
- IMMU-132 infusion is administered to participants in one arm for the study
- IMMU-132 plus Carboplatin infusion
- (no location specified)
Aug 12, 2021
Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States
Recruiting
- Endometrial Serous Adenocarcinoma
- +2 more
- Biopsy
- +3 more
-
Phoenix, Arizona
- +3 more
Feb 2, 2023
Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)
Recruiting
- Recurrent Classic Hodgkin Lymphoma
- Brentuximab Vedotin
- Nivolumab
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 16, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial
Recruiting
- Metastatic Salivary Gland Carcinoma
- +4 more
- Docetaxel
- +3 more
-
New York, New YorkMemorial Sloane Kettering Cancer Center
Jan 11, 2023
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,
Active, not recruiting
- HIV Infection
- +3 more
- brentuximab vedotin
- +3 more
-
Clamart, France
- +5 more
Aug 11, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose
Completed
- Relapsed/Refractory Multiple Myeloma
- Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
-
Phoenix, Arizona
- +10 more
Mar 25, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Withdrawn
- Anatomic Stage IV Breast Cancer AJCC v8
- +3 more
- Abemaciclib
- Trastuzumab Emtansine
-
Yuma, Arizona
- +5 more
May 25, 2022
Metastatic Triple Negative Breast Cancer Trial (Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy
Withdrawn
- Metastatic Triple Negative Breast Cancer
- Sabizabulin
- +2 more
- (no location specified)
Jan 24, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- FOR46
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 1, 2022
Breast Cancer, Non-small Cell Lung Carcinoma Trial in Worldwide (Trastuzumab deruxtecan (DS-8201a), Pembrolizumab)
Recruiting
- Breast Cancer
- Non-small Cell Lung Carcinoma
- Trastuzumab deruxtecan (DS-8201a)
- Pembrolizumab
-
San Francisco, California
- +24 more
Nov 30, 2022
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,
Active, not recruiting
- Classic Hodgkin Lymphoma
- +2 more
- Brentuximab Vedotin
- +2 more
-
Duarte, California
- +5 more
Mar 17, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022